REMARKS

The specification is amended above to insert a reference to related cases.

Claims 11, 12, 13, 16, 21 and 22 have been amended above to remove multiple dependencies, and to better format the claims for accepted US Patent practice.

New Claims 23, 24 and 25 are added to remove multiple dependencies in claims 11, 12 and 13.

No change of inventorship is necessitated by these amendments.

Early allowance of the claims is requested. Should the Examiner believe that a conference with applicants' attorney would advance prosecution of this application, he is respectfully invited to call applicants' attorney.

Dated

(847)383-3372 (847)383-3391 Respectfully submitted,

Mark Chao, Ph.D., Reg. No. 37,293

Elaine M. Ramesh, Ph.D., Reg. No. 43032

Attorney for Applicants Customer No. 23115

Takeda Pharmaceuticals North America, Inc. Intellectual Property Department 475 Half Day Road Lincolnshire, IL 60069 USA